Mirum Pharmaceuticals Price to Free Cash Flow Ratio 2019-2024 | MIRM

Mirum Pharmaceuticals price to free cash flow ratio from 2019 to 2024. Price to free cash flow ratio can be defined as

Mirum Pharmaceuticals Price to Free Cash Flow Ratio 2019-2024 | MIRM

Mirum Pharmaceuticals price to free cash flow ratio from 2019 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$180.5B
Regeneron Pharmaceuticals (REGN)$126.8B
Vertex Pharmaceuticals (VRTX)$123.3B
Gilead Sciences (GILD)$104.5B
Bristol Myers Squibb (BMY)$99.4B
CSL (CSLLY)$97.5B
GSK (GSK)$86.3B
Alnylam Pharmaceuticals (ALNY)$35.5B
Argenex SE (ARGX)$32.1B
Biogen (BIIB)$29.3B
BioNTech SE (BNTX)$26.8B
Moderna (MRNA)$26.1B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$19.3B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.6B
Exact Sciences (EXAS)$13.1B
Vaxcyte (PCVX)$13.1B
Insmed (INSM)$12.9B
Incyte (INCY)$12.9B
Bio-Techne Corp (TECH)$12.7B
Sarepta Therapeutics (SRPT)$12.1B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.9B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Exelixis (EXEL)$7.7B